

Investigation of the effects of estrogen on skeletal gene expression during zebrafish larval head development

Ehsan Pashay Ahi, Benjamin S Walker, Christopher S Lassiter, Zophonías O Jónsson

The development of craniofacial skeletal structures requires well-orchestrated tissue interactions controlled by distinct molecular signals. Disruptions in normal function of these molecular signals have been associated with a wide range of craniofacial malformations. A pathway mediated by estrogens is one of those molecular signals that plays role in formation of bone and cartilage including craniofacial skeletogenesis. Studies in zebrafish have shown that while higher concentrations of 17- β estradiol (E_2) cause severe craniofacial defects, treatment with lower concentrations result in subtle changes in head morphology characterized with shorter snout and flatter face. The molecular basis for these morphological changes, particularly the subtle skeletal effects mediated by lower E_2 concentrations, remains unexplored. In the present study we address these effects at a molecular level by quantitative expression analysis of sets of candidate genes in developing heads of zebrafish larvae treated with two different E_2 concentrations. To this end, we first validated three suitable reference genes, *ppia2*, *rpl8* and *tbp*, to permit sensitive quantitative real-time PCR analysis. Next, we profiled the expression of 28 skeletogenesis-associated genes that potentially respond to estrogen signals and play role in craniofacial development. We found E_2 mediated differential expression of genes involved in extracellular matrix (ECM) remodelling, *mmp2/9/13*, *sparc* and *timp2a*, as well as components of skeletogenic pathways, *bmp2a*, *erf*, *ptch1/2*, *rankl*, *rarab* and *sfrp1a*. Furthermore, we identified a co-expressed network of genes, including *cpn1*, *dnajc3*, *esr1*, *lman1*, *rrbp1a*, *ssr1* and *tram1* with a stronger inductive response to a lower dose of E_2 during larval head development.

1 Investigation of the effects of estrogen on skeletal gene 2 expression during zebrafish larval head development

3
4 Ehsan Pashay Ahi¹,
5 Email: epa1@hi.is

6
7 Benjamin S. Walker²
8 Email: bswalker@mail.roanoke.edu

9
10 Christopher S. Lassiter²
11 Email: lassiter@roanoke.edu

12
13 Zophonías O. Jónsson^{1,3}
14 Email: zjons@hi.is

15
16

17 1 Institute of Life and Environmental Sciences, University of Iceland, Sturlugata 7, 101
18 Reykjavik, Iceland.

19 2 Biology Department, Roanoke College, Salem VA, USA

20 3 Biomedical Center, University of Iceland, Vatnsmýrarvegur 16, 101 Reykjavik, Iceland.

21

22 Abstract

23 The development of craniofacial skeletal structures requires well-orchestrated tissue interactions
24 controlled by distinct molecular signals. Disruptions in normal function of these molecular
25 signals have been associated with a wide range of craniofacial malformations. A pathway
26 mediated by estrogens is one of those molecular signals that plays role in formation of bone and
27 cartilage including craniofacial skeletogenesis. Studies in zebrafish have shown that while higher
28 concentrations of 17- β estradiol (E_2) cause severe craniofacial defects, treatment with lower
29 concentrations result in subtle changes in head morphology characterized with shorter snout and
30 flatter face. The molecular basis for these morphological changes, particularly the subtle skeletal
31 effects mediated by lower E_2 concentrations, remains unexplored. In the present study we
32 address these effects at a molecular level by quantitative expression analysis of sets of candidate
33 genes in developing heads of zebrafish larvae treated with two different E_2 concentrations. To
34 this end, we first validated three suitable reference genes, *ppia2*, *rpl8* and *tbp*, to permit sensitive

35 quantitative real-time PCR analysis. Next, we profiled the expression of 28 skeletogenesis-
36 associated genes that potentially respond to estrogen signals and play role in craniofacial
37 development. We found E₂ mediated differential expression of genes involved in extracellular
38 matrix (ECM) remodelling, *mmp2/9/13*, *sparc* and *timp2a*, as well as components of
39 skeletogenic pathways, *bmp2a*, *erf*, *ptch1/2*, *rankl*, *rarab* and *sfrp1a*. Furthermore, we identified
40 a co-expressed network of genes, including *cpn1*, *dnajc3*, *esr1*, *lman1*, *rrbp1a*, *ssr1* and *traml*
41 with a stronger inductive response to a lower dose of E₂ during larval head development.

42

43 Introduction

44 Craniofacial development is a critical part of embryogenesis and identification of molecular
45 mechanisms underlying this process is important in gaining a better understanding of
46 morphological diversity in vertebrates (Szabo-Rogers et al., 2010) as well as human health
47 (Oginni & Adenekan, 2012). The viscerocranium in humans is of interest because of oro-facial
48 clefts and associated malformations (Marazita, 2012). The vertebrate craniofacial skeleton,
49 including the viscerocranium, is built from neural-crest derived tissues. Changes in these tissues
50 over evolutionary time have given rise to a wide diversity of facial morphologies among
51 vertebrate species (Trainor, Melton & Manzanares, 2003; Bronner & LeDouarin, 2012).

52 Estrogens, steroid hormones synthesized by aromatase from androgenic precursors, have recently
53 been shown to affect craniofacial development (Fushimi et al., 2009; Cohen et al., 2014).
54 Though estrogens are normally thought of as sex hormones, they affect a variety of tissues
55 including the cardiovascular and skeletal systems (Hall, Couse & Korach, 2001; Allgood et al.,
56 2013; Cohen et al., 2014). Estrogens signal through classical nuclear receptors (ER-alpha and
57 ER-beta) (Jia, Dahlman-Wright & Gustafsson, 2015) and a G-protein coupled receptor, GPR-30
58 (Jenei-Lanzl et al., 2010). These signaling proteins are found in the chondrocytes of many
59 vertebrate species (Tankó et al., 2008) and are present during chondrogenesis (Jenei-Lanzl et al.,
60 2010; Elbaradie et al., 2013). Among vertebrates, teleost fish are highly diversified in
61 craniofacial morphology and estrogen has been shown to greatly affect chondrogenesis in many
62 of the fish species studied so far, including tilapia, fathead minnow, and zebrafish (Ng, Datuin &
63 Bern, 2001; Warner & Jenkins, 2007; Cohen et al., 2014). Furthermore, the teleost zebrafish is a
64 well-developed model system for studying both embryonic development and human disease and

65 it can be useful in understanding the development of the human viscerocranial skeleton as these
66 processes are well-conserved among vertebrates (Kuratani, Matsuo & Aizawa, 1997).

67 Low concentrations of estrogen cause subtle changes in craniofacial morphogenesis during
68 zebrafish larval development (Cohen et al., 2014). These changes are characterized by a shorter
69 snout, flatter face and wider angles of cartilage elements in the viscerocranium (Cohen et al.,
70 2014). Another recent study has also demonstrated that an estrogen mediated signal underlies the
71 evolution of shorter snouts and flatter faces in females of some reptilian species (Sanger et al.,
72 2014). These observations suggest that similar mechanisms might underpin hormone-based
73 phenotypic plasticity and diversity (Dufty, 2002), as well as subtle differences in head/skeletal
74 morphology of dimorphic sexes (Loth & Henneberg, 2001; Fujita et al., 2004; Callewaert et al.,
75 2010). Therefore, studies offering insights into molecular mechanisms rendering the observed
76 phenotypes caused by hormonal changes would be called for.

77 The subtle changes in craniofacial skeletogenesis mediated by low concentrations of Estradiol
78 (E_2) are likely to be a result of differences in level and timing of the expression of
79 skeletogenesis-associated genes during head development (Albertson et al., 2010; Ahi et al.,
80 2014; Gunter, Koppermann & Meyer, 2014; Powder et al., 2015). These morphological changes
81 were only revealed by careful measurements of skeletal elements at zebrafish larval stages
82 (Cohen et al., 2014), therefore the identification of responsible genes might also require precise
83 expression studies in developing heads of zebrafish larvae using a sensitive tool such as
84 quantitative real-time PCR (qPCR) (Bustin, 2000; Kubista et al., 2006). In the present study, we
85 set out to quantitatively assess the effects of estrogen on the expression dynamics of candidate
86 genes which are known as potential targets of estrogen pathway and also involved in craniofacial
87 skeletogenesis in different vertebrate species (Table 1). We hypothesized that these genes may be
88 critical to the estrogen modulation of craniofacial skeletogenesis. We first identified the most
89 stably expressed reference genes in developing heads of zebrafish treated with two doses of
90 estrogen ($2\mu\text{M}$ and $5\mu\text{M}$) across five stages in larval development. Then, we accurately
91 measured small changes in the expression levels of the candidate genes. In addition, we have
92 used available co-expression data from zebrafish to identify a co-expressed network of genes
93 with greater transcriptional response to the lower dose of estrogen ($2\mu\text{M}$) during larval head
94 development.

95

96 **Methods**

97 **Fish husbandry, treatment and sampling**

98 Adult zebrafish were fed a diet of live brine shrimp supplemented with Ziegler zebrafish diet
99 (Pentair) and maintained on a 14/10 day/night cycle. Embryos were raised in E3B (5 mM NaCl,
100 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM MgSO₄, 0.00025% methylene blue). Embryos were
101 treated with estrogen (17 β -estradiol, E₂, Sigma) dissolved in ethanol and diluted in E3B for a
102 final ethanol concentration of 0.1%. Control fish were treated with 0.1% ethanol with no
103 developmental malformations as described previously (Cohen et al., 2014). For each treatment
104 group (estrogen concentration), zebrafish larva were raised in Petri dishes, and treatment
105 solutions were refreshed daily until the stages indicated (3, 4, 5, 6 and 7 days post fertilization,
106 dpf). Three biological replicates of 30 larva were collected at each time-point (3-7 dpf) and for
107 each treatment group (control, 2 μ M E₂, and 5 μ M E₂) for a total of 90 larva at each time-point
108 and treatment. The fishes were anesthetized with 0.4% tricaine (MS-222, Sigma). Isolated heads
109 (anterior to the yolk sac) were placed into RNAlater (Qiagen) and stored frozen until RNA
110 isolation. Zebrafish experiments were performed under the Roanoke College IRB protocol
111 #14BIO76.

112

113 **RNA isolation and cDNA synthesis**

114 Around 30 heads of zebrafish from each treatment group and larval stage were pooled in TRI
115 Reagent (Sigma) and homogenized with a disposable Kontes Pellet Pestle Cordless Motor tissue
116 grinder (Kimble Kontes). RNA was prepared according to manufacturer's instructions and
117 dissolved in 50 μ l RNase-free water. RNA samples were treated with DNase (New England
118 Biolabs) to remove contaminating DNA. Quantity of the resulting RNA samples was assessed
119 using a NanoDrop ND-1000 UV/Vis-Spectrophotometer (NanoDrop Technologies). The quality
120 of the RNA samples was evaluated by agarose gel electrophoresis and all samples displayed
121 intact 28 S and 18 S rRNA without noticeable high molecular weight genomic DNA
122 contamination. cDNA was prepared from 1000 ng of RNA using the High capacity cDNA
123 Reverse Transcription kit (Applied Biosystems), according to manufacturer's protocol. Several
124 samples without addition of reverse transcriptase (-RT samples) were prepared to confirm the

125 absence of genomic DNA. cDNA was diluted 3 fold in water for further use in quantitative real-
126 time PCR.

127

128 **Gene selection, Primer design and real-time qPCR**

129 In order to validate suitable reference genes for accurate measurement of the transcriptional
130 changes of candidate genes by qPCR, we selected 7 potential reference genes based on published
131 studies in zebrafish (Table S1) (McCurley & Callard, 2008; Pelayo et al., 2012; Schiller et al.,
132 2013), none of which have been validated during development or in zebrafish head. In addition
133 we selected 28 target genes that are known as potential targets of the estrogen pathway in
134 different vertebrate species, and also involved in craniofacial skeletal formation/morphogenesis
135 (Table 1 and Table S1). Finally, we extended our list of candidates by adding more genes
136 showing co-expression with the estrogen receptor *esr1* based on the zebrafish database
137 COXPRESdb (<http://coexpresdb.jp/>) version 6.0 (Obayashi & Kinoshita, 2011). To obtain the
138 maximum number of coexpressed genes with a high degree of reliability, we filtered the genes
139 by setting the mutual rank (MR) to the top-ranked 2000 and the Supportability score of minimum
140 1 (as described by Obayashi and Kinoshita, 2011). This yielded 338 candidate genes, and from
141 them, we selected 11 genes with reported craniofacial expression during zebrafish development
142 according to the ZFIN database (<http://zfin.org>) (Bradford et al., 2011) (Table S1).

143 Locations overlapping exon boundaries of the genes in zebrafish were determined by NCBI
144 Spidey software (www.ncbi.nlm.nih.gov/spidey) and annotated genome sequences in the
145 Ensembl database (http://www.ensembl.org/Danio_rerio). The qPCR Primers were designed on
146 exon boundaries using Primer Express 3.0 software (Applied Biosystems, Foster City, CA, USA)
147 and checked for self-annealing, hetero-dimers and hairpin structures with OligoAnalyzer 3.1
148 (Integrated DNA Technology) (Table S1).

149 Real-time PCR was performed in 96 well-PCR plates on an ABI 7500 real-time PCR System
150 (Applied Biosystems) using Maxima SYBR Green/ROX qPCR Master Mix (2X) as
151 recommended by the manufacturer (Thermo Fisher Scientific, St Leon-Rot, Germany). Each
152 biological replicate was run in duplicate together with no-template control (NTC) in each run for
153 each gene and experimental set-up per run followed the preferred sample maximization method
154 (Hellemans et al., 2007). The qPCR was run with a 2 min hold at 50°C and a 10 min hot start at
155 95°C followed by the amplification step for 40 cycles of 15 sec denaturation at 95°C and 1 min

156 annealing/extension at 60°C. A dissociation step (60°C – 95°C) was performed at the end of the
157 amplification phase to identify a single, specific product for each primer set (Table S1). Primer
158 efficiency values (E) were calculated with the LinRegPCR v11.0 programme
159 (<http://LinRegPCR.nl>) (Ramakers et al., 2003) analysing the background-corrected fluorescence
160 data from the exponential phase of PCR amplification for each primer-pair and those with E less
161 than 0.9 were discarded and new primers designed (Table S1).

162

163 **Data analysis**

164 To detect the most stably expressed reference genes, three ranking algorithms; BestKeeper
165 (Pfaffl et al., 2004), NormFinder (Andersen, Jensen & Ørntoft, 2004) and geNorm
166 (Vandesompele et al., 2002), were employed. The standard deviation (SD) based on Cq values of
167 the larval stages and treatment groups was calculated by BestKeeper to determine the expression
168 variation for each reference gene. In addition, BestKeeper determines the stability of reference
169 genes based on correlation to other candidates through calculation of BestKeeper index (r).
170 GeNorm measures mean pairwise variation between each gene and other candidates, the
171 expression stability or *M* value, and it excludes the gene with the highest *M* value (least stable)
172 from subsequent analysis in a stepwise manner. Moreover, geNorm determines the optimal
173 number of reference genes through calculation of pairwise variation coefficient ($V_n/n+1$)
174 between two sequential normalisation factors (NF_n and NF_{n+1}) and extra reference genes are
175 added until the variation drops below the recommended threshold of 0.15 (Vandesompele et al.,
176 2002). NormFinder identifies the most stable genes (lowest expression stability values) based on
177 analysis of the sample subgroups (stage and treatment group) and estimation of inter- and intra-
178 group variation in expression levels.

179 For the analysis of qPCR data, the difference between Cq values (ΔCq) of the reference genes
180 and the target genes was calculated for each gene; $\Delta Cq_{\text{target}} = Cq_{\text{target}} - Cq_{\text{reference}}$. The
181 geometric mean of Cq values of three best ranked reference genes, *ppia2*, *rpl8* and *tbp* (see the
182 ranking algorithms above), was used as $Cq_{\text{reference}}$ in the ΔCq calculations. All samples were then
183 normalized to the ΔCq value of a calibrator sample to obtain a $\Delta\Delta Cq$ value ($\Delta Cq_{\text{target}} - \Delta Cq_{\text{calibrator}}$).
184 For each primer pair a biological replicate in the control group at 3dpf was selected as
185 the calibrator sample. Relative expression quantities (RQ) were calculated based on the
186 expression level of the calibrator sample ($E^{-\Delta\Delta Cq}$) (Pfaffl, 2001). The RQ values were then

187 transformed to logarithmic base 2 values (or fold differences; FD) for statistical analysis
188 (Bergkvist et al., 2010). A two-way analysis of variance (ANOVA) followed by post hoc Tukey's
189 honest significant difference (HSD) test was implemented for each reference or target gene with
190 larval stages and treatment groups as categorical variables. To assess similarities in expression
191 patterns of the genes Pearson correlation coefficients (r) were calculated for all gene pairs using
192 the data from 3 treatments at 5 larval stages (degree of freedom = 13). R ([http://www.r-](http://www.r-project.org)
193 [project.org](http://www.r-project.org)) was used for all statistical analysis.

194

195

196 **Results**

197

198 ***tbp*, *ppia2* and *rpl8* are the most suitable reference genes**

199 Real-time quantitative PCR for the 7 reference gene candidates was performed on cDNA
200 generated from zebrafish head homogenates in three treatment groups at five larval stages. The
201 expression levels of the candidates varied from *ppia2*, with the highest expression (lowest Cq)
202 (Fig. 1A), to *tbp* with the lowest expression (highest Cq). Statistical analysis revealed that all of
203 the candidates except *actb1* are stably expressed between the treatment groups (Fig. 1B).
204 However, only *tbp* showed constant expression during the larval stages examined. Two genes,
205 *ppia2* and *rpl8*, were also stably expressed in developing heads of zebrafish larvae except for the
206 first stage (3dpf). Based on these results *tbp* followed by *ppia2* and *rpl8* were found to be the
207 overall most stable reference genes both over time and between the treatment groups. The
208 candidate reference genes were ranked using three algorithms, *i.e.* BestKeeper, geNorm and
209 NormFinder, and based on standard deviation (SD) as described in (Ahi et al., 2013) (Table 2).
210 In all of the analyses three genes; *ppia2*, *rpl8* and *tbp*, were the three highest ranking candidates,
211 however their order varied between the rankings (Table 2). Furthermore, geNorm suggested the
212 use of the three best ranked candidate genes as sufficient for accurate normalisation (Fig. S1).
213 The data reflect the high expression stability of the best ranked candidate genes and suggests the
214 combination of *ppia2*, *rpl8* and *tbp* as a suitable and sufficient normalization factor to accurately
215 quantify small differences in gene expression in developing heads of zebrafish larvae across the
216 E₂ treatment groups.

217

218 Components of different signalling pathways and skeletogenesis-associated
219 genes are affected by estrogen during larval head development

220 The selected 28 candidate target genes, listed in Table 1, can be classified into distinct functional
221 groups; (I) estrogen receptors with potential involvement in vertebrate craniofacial development
222 (*esrra* and *esr1*); (II) components of hedgehog (Hh) signaling pathway (*ptch1/2* and *shha/b*);
223 (III) potential skeletogenic targets of estrogen pathway with critical roles in viscerocranial
224 development/ morphogenesis (*bmp2a/b*, *opg*, *rankl*, *runx2b* and *sox9b*); (IV) potential targets of
225 estrogen pathway involved in ECM formation and associated with shortened snout
226 morphogenesis in vertebrates (*col2a1a*, *ctsk*, *mmp2/9/13*, *sparc*, *spp1* and *timp2a*); and (V) other
227 potential targets of estrogen pathways with diverse functions which are also involved in
228 viscerocranial skeletogenesis (*alx4*, *dlk1*, *erf*, *ets2*, *pbx1a/b*, *rarab* and *sfrpl1a*). The expression
229 levels of all candidates were measured in the three treatment groups during larval head
230 development (Fig. 2-5). We found effects of different E₂ concentrations on the expression of
231 most of the target genes, except *col2a1a* and *pbx1a*, the effects, however, were highly variable
232 among the genes (Fig. 2-5). For instance, while some genes, i.e. *esr1*, *ptch1/2* and *rarab*
233 displayed differential expression between the treatment groups at most of the larval stages, other
234 genes such as *alx4*, *bmp2b*, *ctsk*, *ets2*, *opg*, etc., showed expression differences at only one stage.
235 Among the more highly affected genes, *erf*, *esrra*, *mmp9*, *rankl*, *shha*, *sfrpl1a*, *sparc* and *timp2a*
236 were differentially expressed in at least three larval stages (Fig. 2-5). Although significant, most
237 differences in expression levels of the target genes were slight between the treatment groups (RQ
238 < 0.5), except for *esr1* at the last larval stages (Fig. 2). Moreover, for all of the affected genes,
239 except *esr1* and *mmp13*, the different E₂ treatments had mainly repressive effects on
240 transcription. These repressive effects were not, however, increased by higher E₂ concentration
241 particularly at the last two stages when the lower E₂ dose (2μM) repressed expression of many of
242 the genes more than the higher dose. At the last three stages, the expression of *esr1* was induced
243 at highest levels for 2μM treatment groups (Fig. 2). The transcriptional repression by E₂ was also
244 variable between the genes and it was more pronounced for *erf* and *ptch2* showing higher
245 expression in control groups than both E₂ treated groups at three larval stages. Taken together,
246 these results show significant effects of low E₂ concentrations on the expression of a variety of
247 genes involved in skeletogenesis and/or craniofacial development.

248 We calculated the Pearson's correlation coefficient of the expression levels for the target genes
249 over all treatment groups and larval stages and found positive expression correlation between
250 many pairs of target genes (blue shadings in Fig. S2). Some of the genes i.e. *mmp9*, *ptch1*, *rarab*
251 and *timp2a* displayed positive expression correlation with most of the genes whereas others such
252 as *mmp13*, *sfrp1a*, *shhb* and *sparc* showed the least correlated expression. Negatively correlated
253 expression was only seen between *esr1* and *sfrp1a*, and between *shhb* and six genes including
254 *esr1*, *ets2*, *mmp13*, *opg*, *pbx1a* and *spp1* (red shadings in Fig. S2).

255

256 **A co-expressed network of genes shows higher expression induction in lower** 257 **E₂ treatment groups**

258 The stronger transcriptional response of *esr1* to the lower E₂ treatment (Fig. 2) could indicate a
259 distinct regulatory mechanism associated with slight increase in estrogen concentration during
260 zebrafish larval head development. In order to identify additional genes showing similar
261 expression dynamics, we selected 11 candidate genes constructing a co-expression network with
262 *esr1* using co-expression data for zebrafish in COXPRESdb (Obayashi & Kinoshita, 2011)
263 (Table S2). These candidates are also known to have craniofacial skeletal expression during
264 zebrafish development based on data submitted to ZFIN database (<http://zfin.org>) (Bradford et
265 al., 2011). Strikingly, we found stronger inductive effects of the lower E₂ concentration on the
266 expression of six genes, i.e. *cpn1*, *dnajc3*, *lman1*, *rrbp1a*, *ssr1* and *tram1* (Fig. 6). The
267 expression of these six genes followed a similar pattern and their higher expression levels were
268 more pronounced at the last three stages of 2μM treatment groups. Moreover, the gene showing
269 strongest coexpression relationship with *esr1* among the candidates, *rrbp1a*, had shown higher
270 expression levels at the last four stages of 2μM treatment groups (Table S2 and Fig. 6). Finally,
271 we also demonstrated positive expression correlations between the six candidates and *esr1*, but
272 not the rest of the non-differentially expressed genes (blue shadings in Fig. S3).

273

274 **Discussion**

275 Estrogen signaling, through both canonical nuclear estrogen receptors and G-protein coupled
276 receptors, is important in embryonic development (Griffin et al., 2013; Shi et al., 2013).
277 Estrogens can act at autocrine, paracrine, and endocrine distances in the embryo and the adult

278 (Boon, Chow & Simpson, 2010). Aromatase, the enzyme that synthesizes estrogens, is present in
279 the developing brain of many species, including zebrafish (Lassiter & Linney, 2007) and would
280 be a local source of the hormone during head development. In fact, the teleost brain produces
281 relatively high levels of estrogen compared to other vertebrates (Forlano et al., 2001). Estrogens
282 are thus present in the cranium of developing embryos and modulate viscerocranial development
283 (Fushimi et al., 2009; Marquez Hernandez et al., 2011; Cohen et al., 2014). Estrogen signalling
284 has been implicated in the sexual dimorphism of cranial bones in the Anolis lizard (Sanger et al.,
285 2014). Hence, it may play a role in craniofacial morphological divergence among species and
286 within sexes of the same species.

287 A previous attempt to identify mechanisms underlying the effects of estrogen on zebrafish
288 craniofacial development was conducted with a high concentration of 17- β estradiol (10 μ M)
289 giving rise to major disruptions of chondrogenesis followed by severe morphological defects
290 (Fushimi et al., 2009). In the same study, analysis of gene expression after high dose estrogen
291 treatment was limited to a semi-quantitative method (*in situ* hybridization) and a few
292 chondrogenic genes belonging to only one molecular pathway (Fushimi et al., 2009). We
293 hypothesized that many other candidate genes would be involved and hence, in the present study,
294 we sought to quantitatively assess the expression of genes that could play role in the subtle
295 effects of estrogen on the development of the craniofacial skeleton in zebrafish larvae (Cohen et
296 al., 2014). Since our expression analysis depended on accurate qPCR, a prior step of careful
297 validation of reference genes was essential to acquire reliable results (Bustin, 2000; Kubista et
298 al., 2006). An increasing number of stably expressed reference genes have been validated for
299 qPCR studies in a variety of fish species (Ahi et al., 2013; Fuentes et al., 2013; Liu et al., 2014;
300 Altmann et al., 2015; Wang et al., 2015), and also in zebrafish at different developmental stages,
301 body parts/tissues, and treatments (Tang et al., 2007; McCurley & Callard, 2008; Lin et al.,
302 2009; Casadei et al., 2011). There is however a necessity for validation of reference genes
303 depending on the experimental conditions under study. Here, we found three genes, *ppia2*, *rpl8*
304 and *tbp*, to be the most stably expressed candidate genes by all the methods of analysis used
305 (Table 2 and Fig.1) and their combination could ensure robust qPCR data normalisation (Fig.
306 S1). We next selected candidate genes that are shown to be potential estrogen pathway targets,
307 and at the same time, differential regulation of many of them is associated with morphological
308 changes resembling shortened snout in different vertebrates (many found in mammalian species)

309 (see publications referenced in Table 1). The underlying mechanisms by which these candidate
310 genes could affect skeletogenesis are different from each other. For instance, genes like *bmp2a/b*,
311 *rankl*, *runx2b* and *sox9b* are major factors in differentiation of skeletal cells and some others
312 such as *col2a1a*, *ctsk*, *mmp2/9/13*, *spp1* and *sparc* are critical for the formation of ECM in
313 craniofacial skeletal structures (see Table 1).

314 The treatments with the two different doses of E₂ (2 and 5 μM) resulted in differential expression
315 of many of the candidates during the zebrafish larval head development (Fig. 2-5). Consistent
316 with a previous study in zebrafish using higher E₂ concentration (10 μM) (Fushimi et al., 2009),
317 we also found significant down-regulation of *ptch1* and *ptch2* in the heads of fish receiving
318 lower dose estrogen treatments during larval development. These two genes are the receptors
319 (and the upstream mediators) of the hedgehog (Hh) signaling pathway which plays a crucial role
320 in developmental patterning and skeletal morphogenesis (Eberhart et al., 2006; Swartz et al.,
321 2012). Interestingly, slight changes in expression of *ptch1* were shown to be associated with
322 subtle craniofacial skeletal divergence (shorter snout and flatter face) in cichlid fish (Roberts et
323 al., 2011; Hu & Albertson, 2014). In addition, we found a strong positive expression correlation
324 between *ptch1* and *ptch2* (Fig. S2), indicating potential estrogen mediated co-regulation of the
325 two Hh receptors. In the above mentioned study of high dose E₂ treatment, the upstream
326 activators of the Hh pathway, sonic hedgehog genes, *shha* and *shhb* (*twhh*), did not show
327 significant changes in expression (Fushimi et al., 2009). However, this could be due to technical
328 limitations such as the use of a semi-quantitative method that is unable to reveal small
329 differences in gene expression (Fushimi et al., 2009). In this study we found small and yet
330 significant down-regulation of *shha*, but not *shhb*, in E₂ treated groups, as well as positive co-
331 expression of only *shha* with the two Hh receptors. An important role of the *shh* in craniofacial
332 skeletogenesis through activation of Hh signalling has been described (Hu & Helms, 1999), but it
333 is not clear whether estrogen directly regulates its expression during development. The small
334 reduction of *shha* transcripts in developing larval heads might be a result of a decreased number
335 of cells expressing *shha* and not direct estrogen mediated transcriptional regulation.

336 Extracellular matrix remodelling is a critical process in the developmental program of bone and
337 cartilage differentiation and morphogenesis (Werb & Chin, 1998). The spatio-temporal
338 expression of genes encoding matrix metalloproteinases and their tissue inhibitors plays a pivotal
339 role in orchestrating the ECM remodelling process (Werb & Chin, 1998; Page-McCaw, Ewald &

340 Werb, 2007). Moreover, many ECM remodelling genes are downstream targets of pathways
341 mediated by nuclear receptors, including estrogen signalling (Cox & Helvering, 2006; Heldring
342 et al., 2007; Ganesan et al., 2008). The selected ECM remodelling factors (*mmp2/9/13*, *timp2a*
343 and *sparc*) were all reported to be regulated by estrogen signalling (Lehane et al., 1999; Tüshaus
344 et al., 2003; Marin-Castaño et al., 2003; Lu et al., 2006; Nilsson, Garvin & Dabrosin, 2007; Lam
345 et al., 2009; Wang & Ma, 2012) and play role in craniofacial skeletal morphogenesis (Dew et al.,
346 2000; Renn et al., 2006; Hillegass et al., 2007a,b; Mosig et al., 2007; Rotllant et al., 2008; Letra
347 et al., 2012; Ahi et al., 2014). Our results revealed slight but significant effects of the estrogen
348 treatments on expression of the selected ECM remodelling genes during larval head development
349 (Fig. 4). It is interesting to note that previous investigations have shown association between
350 differential expression of these genes and craniofacial phenotypes with flatter face and shorter
351 snout (Hillegass et al., 2007a,b; Ahi et al., 2014). The mechanism by which estrogen regulates
352 the expression of ECM remodelling genes is not well understood. The estrogen dependent
353 regulation might be exerted through interaction between estrogen-receptors and transcription
354 factors that regulate ECM remodelling genes such as members of Ap-1 complex and ETS factors
355 (Lu et al., 2006; Ahi et al., 2014; Cao et al., 2015). The binding motifs for Ap-1 and ETS
356 transcription factors are present in the promoters of many ECM remodelling genes across
357 vertebrate species (Ahi et al., 2014). Additionally, we found the expression of *erf*, an ETS
358 repressor and estrogen target (Sgouras et al., 1995), to be down-regulated in both E₂ treated
359 groups at three larval stages. Remarkably, a recent study showed that small reduction in
360 expression of *erf* causes complex craniosynostosis with shortened snout in both human and mice
361 (Frasor et al., 2003; Twigg et al., 2013). The same study also demonstrated regulatory elements
362 containing Ap-1, ETS and Runx motifs as preferential *erf* binding sites (Twigg et al., 2013).
363 Taken together, the results of the present and previous studies suggest potential estrogen
364 mediated regulation of ECM remodelling genes possibly through interaction with other
365 transcription factors. Other estrogen mediated processes than direct transcriptional regulation
366 cannot, however, be ruled out, as the slight changes in transcript levels of ECM related genes
367 could be due to reduced proportion of skeletal cells expressing these genes in larval heads. It is
368 also important to emphasize that the selected ECM genes can be expressed in other tissues of the
369 head (though at considerably lower levels), thus their expression differences in other tissues
370 might affect the overall changes in expression.

371 The E₂ treatments caused small and variable repressive effects on expression of other selected
372 target genes (Fig. 2-5). The genes, *bmp2a* and *rankl*, are well characterized skeletogenic markers
373 (Nie, Luukko & Kettunen, 2006; Hu, Colnot & Marcucio, 2008; Lézot et al., 2015) and their
374 regulation by estrogen signalling has been reported in other vertebrate species (Bord et al., 2003;
375 Zhou et al., 2003). It has been shown that treatment with high doses of E₂ can reduce the number
376 of skeletal cells in the craniofacial skeleton (Cohen et al., 2014), hence the small changes in
377 transcript levels of skeletogenic markers (e.g. *sox9b*) may again be caused by a decreased
378 proportion of skeletal cells in the heads. We also found components of retinoic acid and Wnt/ β -
379 catenin signalling pathways, *rarb* and *sfrp1a*, to be transcriptionally affected by E₂ treatment
380 indicating the potential crosstalk of these pathways with estrogen signalling during larval head
381 development (Lohnes et al., 1994; O'Lone et al., 2004; Trevant et al., 2008; Yokota et al., 2008).
382 Although, the selected components of the pathways and transcription factors in this study (Fig. 5)
383 are known to have markedly high levels of expression in the craniofacial skeleton, they might
384 also be expressed to a lesser extent in other tissues within the larval head. Therefore, the
385 observed small changes in expression can not be readily attributed to viscerocranial skeletal
386 elements and further gene expression studies using dissected skeletal elements are essential to
387 confirm this.

388 In addition to skeletogenic genes, we were interested in investigating the effects of different
389 doses of E₂ on the expression of estrogen receptors. Therefore, we assessed the expression of two
390 estrogen receptors, *esrra* and *esr1*, that could mediate estrogen signal during the development of
391 skeletal tissues (Bonnelye & Aubin, 2005; Bonnelye et al., 2007; Auld et al., 2012). While the E₂
392 treatments had small and variable repressive effects on expression of *esrra*, the increased
393 expression of *esr1* was observed in both E₂ treated groups. Strikingly, the lower E₂ concentration
394 (2 μ M) resulted in higher induction of *esr1* expression. This suggests that the distinct effects of
395 lower doses of estrogen on craniofacial skeletogenesis, described by Cohen et al., 2014, might be
396 mediated by *esr1*, however further functional studies are required to demonstrate such a role. To
397 identify genes sharing regulatory mechanisms in response to slight increases in estrogen levels,
398 we further explored the expression of 11 genes constructing a co-expression network with *esr1*
399 (Table S2 and Fig. 6). These candidate genes were selected by using a vertebrate co-expression
400 database (Obayashi & Kinoshita, 2011) which we have successfully used for identification of
401 gene networks associated with subtle craniofacial morphological divergence in another teleost

402 (Ahi et al., 2014, 2015). Our results indicate higher transcriptional induction of six genes, i.e.
403 *cpn1*, *dnajc3*, *lman1*, *rrbp1a*, *ssr1* and *tram1* in the lower (2 μ M), than the moderate (5 μ M)
404 treatment groups, during craniofacial development. The genes also showed positive expression
405 correlation with *esr1* suggesting a common regulatory mechanism mediated by estrogen during
406 head development. To our knowledge, a mechanism by which a lower concentration of estrogen
407 can have stronger inductive effects on expression of certain genes than higher concentrations is
408 not known. Such a mechanism might be involved in distinct regulation of estrogen receptors by
409 different concentrations of estrogen hormone, which in turn could lead to recruitment of the
410 receptors to distinct genomic binding sites and/or with different binding affinity (Stender et al.,
411 2010). Among the six genes only *dnajc3*, a gene encoding protein kinase inhibitor P58
412 (P58^{IPK}), has been shown to be involved in skeletogenesis through regulation of a cytokine-
413 dependent cartilage degradation (Gilbert et al., 2014). Although all of the six genes have
414 recorded developmental expression patterns in zebrafish craniofacial elements based on data in
415 the ZFIN zebrafish database (Thisse et al., 2001, 2004), their roles in craniofacial morphogenesis
416 have yet to be investigated. Finally, an unbiased approach such as transcriptome sequencing
417 rather than candidate gene-based study would be warranted to provide better knowledge of
418 estrogen mediated effects on expression of genes with unknown roles in craniofacial
419 morphogenesis as well as links between already identified genes and molecular pathways
420 involved.

421

422 **Conclusions**

423 In this study we quantitatively assessed the effects of two doses of estrogen (2 μ M and 5 μ M) on
424 gene expression during zebrafish larval head development. We performed a highly sensitive and
425 specific qPCR analysis and carefully validated reference genes. We assessed the expression of a
426 selected set of genes involved in craniofacial skeletal development as well as genes coexpressed
427 with *esr1*, an estrogen receptor showing stronger inductive response to 2 μ M than 5 μ M estrogen
428 concentration. The results implicate estrogen in the expressional regulation of genes belonging to
429 distinct signalling pathways such as hedgehog and retinoic acid pathways, as well as genes
430 involved in ECM remodelling during craniofacial development. Furthermore, estrogen mediated
431 transcriptional changes in a few tested major skeletogenic factors (e.g. *bmp2a* and *rankl*), and a
432 transcription factor, *erf*, with a demonstrated role in the formation of a shortened snout

433 phenotype in human and mouse. Finally, we identified a gene network showing positive
434 expression correlation with *esr1* and higher induction in response to treatment with 2 μ M than
435 with 5 μ M estrogen. This could suggest a co-regulated module of genes mediating the effects of
436 low doses of estrogen during craniofacial development which required to be further investigated
437 at functional level.

438

439

440 **Acknowledgements**

441 The authors would like to acknowledge Rebecca Hudon, Sean Ryan, and Alexander Kramer for
442 assistance with zebrafish husbandry and sample isolation.

443

444 **References**

- 445 Abdallah BM., Ditzel N., Mahmood A., Isa A., Traustadottir GA., Schilling AF., Ruiz-Hidalgo
446 M-J., Laborda J., Amling M., Kassem M. 2011. DLK1 is a novel regulator of bone mass
447 that mediates estrogen deficiency-induced bone loss in mice. *Journal of bone and mineral*
448 *research : the official journal of the American Society for Bone and Mineral Research*
449 26:1457–71.
- 450 Ahi EP., Guðbrandsson J., Kapralova KH., Franzdóttir SR., Snorrason SS., Maier VH., Jónsson
451 ZO. 2013. Validation of Reference Genes for Expression Studies during Craniofacial
452 Development in Arctic Charr. *PLoS one* 8:e66389.
- 453 Ahi EP., Kapralova KH., Pálsson A., Maier VH., Gudbrandsson J., Snorrason SS., Jónsson ZO.,
454 Franzdóttir SR. 2014. Transcriptional dynamics of a conserved gene expression network
455 associated with craniofacial divergence in Arctic charr. *EvoDevo* 5:40.
- 456 Ahi EP., Steinhäuser SS., Pálsson A., Franzdóttir SR., Snorrason SS., Maier VH., Jónsson ZO.
457 2015. Differential expression of the Aryl hydrocarbon receptor pathway associates with
458 craniofacial polymorphism in sympatric Arctic charr. *EvoDevo* 6:27.
- 459 Albertson RC., Yan Y-L., Titus TA., Pisano E., Vacchi M., Yelick PC., Detrich HW.,
460 Postlethwait JH. 2010. Molecular pedomorphism underlies craniofacial skeletal evolution in
461 Antarctic notothenioid fishes. *BMC Evolutionary Biology* 10:4.
- 462 Allgood OE., Hamad A., Fox J., Defrank A., Gilley R., Dawson F., Sykes B., Underwood TJ.,
463 Naylor RC., Briggs AA., Lassiter CS., Bell WE., Turner JE. 2013. Estrogen prevents
464 cardiac and vascular failure in the “listless” zebrafish (*Danio rerio*) developmental model.

- 465 *General and comparative endocrinology* 189:33–42.
- 466 Altmann S., Rebl A., Kühn C., Goldammer T. 2015. Identification and de novo sequencing of
467 housekeeping genes appropriate for gene expression analyses in farmed maraena whitefish
468 (*Coregonus maraena*) during crowding stress. *Fish physiology and biochemistry* 41:397–
469 412.
- 470 Andersen CL., Jensen JL., Ørntoft TF. 2004. Normalization of real-time quantitative reverse
471 transcription-PCR data: a model-based variance estimation approach to identify genes
472 suited for normalization, applied to bladder and colon cancer data sets. *Cancer research*
473 64:5245–50.
- 474 Auld KL., Berasi SP., Liu Y., Cain M., Zhang Y., Huard C., Fukayama S., Zhang J., Choe S.,
475 Zhong W., Bhat BM., Bhat RA., Brown EL., Martinez R V. 2012. Estrogen-related receptor
476 α regulates osteoblast differentiation via Wnt/ β -catenin signaling. *Journal of molecular*
477 *endocrinology* 48:177–91.
- 478 Bergkvist A., Rusnakova V., Sindelka R., Garda JMA., Sjögreen B., Lindh D., Forootan A.,
479 Kubista M. 2010. Gene expression profiling--Clusters of possibilities. *Methods (San Diego,*
480 *Calif.)* 50:323–35.
- 481 Bonnelye E., Zirngibl RA., Jurdic P., Aubin JE. 2007. The Orphan Nuclear Estrogen Receptor-
482 Related Receptor- α Regulates Cartilage Formation in Vitro : Implication of Sox9.
483 *Endocrinology* 148:1195–1205.
- 484 Bonnelye E., Aubin JE. 2005. Estrogen receptor-related receptor alpha: a mediator of estrogen
485 response in bone. *The Journal of clinical endocrinology and metabolism* 90:3115–21.
- 486 Boon WC., Chow JDY., Simpson ER. 2010. The multiple roles of estrogens and the enzyme
487 aromatase. *Progress in brain research* 181:209–32.
- 488 Bord S., Ireland D., Beavan S., Compston J. 2003. The effects of estrogen on osteoprotegerin,
489 RANKL, and estrogen receptor expression in human osteoblasts. *Bone* 32:136–141.
- 490 Bradford Y., Conlin T., Dunn N., Fashena D., Frazer K., Howe DG., Knight J., Mani P., Martin
491 R., Moxon SAT., Paddock H., Pich C., Ramachandran S., Ruef BJ., Ruzicka L., Bauer
492 Schaper H., Schaper K., Shao X., Singer A., Sprague J., Sprunger B., Van Slyke C.,
493 Westerfield M. 2011. ZFIN: enhancements and updates to the Zebrafish Model Organism
494 Database. *Nucleic acids research* 39:D822–9.
- 495 Breckon JJW., Papaioannou S., Kon LWM., Tumber A., Hembry RM., Murphy G., Reynolds JJ.,
496 Meikle MC. 1999. Stromelysin (MMP-3) Synthesis Is Up-Regulated in Estrogen-Deficient
497 Mouse Osteoblasts In Vivo and In Vitro. *Journal of Bone and Mineral Research* 14:1880–
498 1890.

- 499 Bronner ME., LeDouarin NM. 2012. Development and evolution of the neural crest: an
500 overview. *Developmental biology* 366:2–9.
- 501 Bustin S. 2000. Absolute quantification of mRNA using real-time reverse transcription
502 polymerase chain reaction assays. *Journal of Molecular Endocrinology* 25:169–193.
- 503 Callewaert F., Sinnesael M., Gielen E., Boonen S., Vanderschueren D. 2010. Skeletal sexual
504 dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. *The*
505 *Journal of endocrinology* 207:127–34.
- 506 Cao P., Feng F., Dong G., Yu C., Feng S., Song E., Shi G., Liang Y., Liang G. 2015. Estrogen
507 receptor α enhances the transcriptional activity of ETS-1 and promotes the proliferation,
508 migration and invasion of neuroblastoma cell in a ligand dependent manner. *BMC cancer*
509 15:491.
- 510 Casadei R., Pelleri MC., Vitale L., Facchin F., Lenzi L., Canaider S., Strippoli P., Frabetti F.
511 2011. Identification of housekeeping genes suitable for gene expression analysis in the
512 zebrafish. *Gene expression patterns : GEP* 11:271–6.
- 513 Cohen SP., LaChappelle AR., Walker BS., Lassiter CS. 2014. Modulation of estrogen causes
514 disruption of craniofacial chondrogenesis in *Danio rerio*. *Aquatic toxicology (Amsterdam,*
515 *Netherlands)* 152:113–20.
- 516 Cox DA., Helvering LM. 2006. Extracellular matrix integrity: a possible mechanism for
517 differential clinical effects among selective estrogen receptor modulators and estrogens?
518 *Molecular and cellular endocrinology* 247:53–9.
- 519 Craig AM., Denhardt DT. 1991. The murine gene encoding secreted phosphoprotein 1
520 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and
521 progesterone. *Gene* 100:163–71.
- 522 Deblois G., Hall JA., Perry M-C., Laganière J., Ghahremani M., Park M., Hallett M., Giguère V.
523 2009. Genome-wide identification of direct target genes implicates estrogen-related receptor
524 alpha as a determinant of breast cancer heterogeneity. *Cancer research* 69:6149–57.
- 525 Dew G., Murphy G., Stanton H., Vallon R., Angel P., Reynolds JJ., Hembry RM. 2000.
526 Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone. *Cell and*
527 *Tissue Research* 299:385–394.
- 528 Dufty A. 2002. Hormones, developmental plasticity and adaptation. *Trends in Ecology &*
529 *Evolution* 17:190–196.
- 530 Eames BF., Singer A., Smith GA., Wood ZA., Yan Y-L., He X., Polizzi SJ., Catchen JM.,
531 Rodriguez-Mari A., Linbo T., Raible DW., Postlethwait JH. 2010. UDP xylose synthase 1 is
532 required for morphogenesis and histogenesis of the craniofacial skeleton. *Developmental*

- 533 *biology* 341:400–15.
- 534 Eberhart JK., Swartz ME., Crump JG., Kimmel CB. 2006. Early Hedgehog signaling from neural
535 to oral epithelium organizes anterior craniofacial development. *Development (Cambridge,*
536 *England)* 133:1069–77.
- 537 Elbaradie KBY., Wang Y., Boyan BD., Schwartz Z. 2013. Sex-specific response of rat
538 costochondral cartilage growth plate chondrocytes to 17 β -estradiol involves differential
539 regulation of plasma membrane associated estrogen receptors. *Biochimica et biophysica*
540 *acta* 1833:1165–72.
- 541 Flores MV., Lam EYN., Crosier P., Crosier K. 2006. A hierarchy of Runx transcription factors
542 modulate the onset of chondrogenesis in craniofacial endochondral bones in zebrafish.
543 *Developmental dynamics : an official publication of the American Association of*
544 *Anatomists* 235:3166–76.
- 545 Forlano PM., Deitcher DL., Myers DA., Bass AH. 2001. Anatomical distribution and cellular
546 basis for high levels of aromatase activity in the brain of teleost fish: aromatase enzyme and
547 mRNA expression identify glia as source. *The Journal of neuroscience : the official journal*
548 *of the Society for Neuroscience* 21:8943–55.
- 549 Frasor J., Danes JM., Komm B., Chang KCN., Lyttle CR., Katzenellenbogen BS. 2003. Profiling
550 of estrogen up- and down-regulated gene expression in human breast cancer cells: insights
551 into gene networks and pathways underlying estrogenic control of proliferation and cell
552 phenotype. *Endocrinology* 144:4562–74.
- 553 Fuentes EN., Safian D., Valdés JA., Molina A. 2013. Isolation and selection of suitable reference
554 genes for real-time PCR analyses in the skeletal muscle of the fine flounder in response to
555 nutritional status: assessment and normalization of gene expression of growth-related genes.
556 *Fish physiology and biochemistry* 39:765–77.
- 557 Fujita T., Ohtani J., Shigekawa M., Kawata T., Kaku M., Kohno S., Tsutsui K., Tenjo K.,
558 Motokawa M., Tohma Y., Tanne K. 2004. Effects of sex hormone disturbances on
559 craniofacial growth in newborn mice. *Journal of dental research* 83:250–4.
- 560 Fukuhara K., Kariya M., Kita M., Shime H., Kanamori T., Kosaka C., Orii A., Fujita J., Fujii S.
561 2013. Secreted Frizzled Related Protein 1 Is Overexpressed in Uterine Leiomyomas,
562 Associated with a High Estrogenic Environment and Unrelated to Proliferative Activity.
563 *The Journal of Clinical Endocrinology & Metabolism*.
- 564 Fushimi S., Wada N., Nohno T., Tomita M., Saijoh K., Sunami S., Katsuyama H. 2009. 17beta-
565 Estradiol inhibits chondrogenesis in the skull development of zebrafish embryos. *Aquatic*
566 *toxicology (Amsterdam, Netherlands)* 95:292–8.
- 567 Ganesan K., Tiwari M., Balachandran C., Manohar BM., Puvanakrishnan R. 2008. Estrogen and

- 568 testosterone attenuate extracellular matrix loss in collagen-induced arthritis in rats. *Calcified*
569 *tissue international* 83:354–64.
- 570 Gilbert SJ., Meakin LB., Bonnet CS., Nowell MA., Ladiges WC., Morton J., Duance VC.,
571 Mason DJ. 2014. Deletion of P58(IPK), the Cellular Inhibitor of the Protein Kinases PKR
572 and PERK, Causes Bone Changes and Joint Degeneration in Mice. *Frontiers in*
573 *endocrinology* 5:174.
- 574 Griffin LB., January KE., Ho KW., Cotter KA., Callard G V. 2013. Morpholino-mediated
575 knockdown of ER α , ER β a, and ER β b mRNAs in zebrafish (*Danio rerio*) embryos reveals
576 differential regulation of estrogen-inducible genes. *Endocrinology* 154:4158–69.
- 577 Gunter HM., Koppermann C., Meyer A. 2014. Revisiting de Beer’s textbook example of
578 heterochrony and jaw elongation in fish: calmodulin expression reflects heterochronic
579 growth, and underlies morphological innovation in the jaws of belonoid fishes. *EvoDevo*
580 5:8.
- 581 Hall JM., Couse JF., Korach KS. 2001. The Multifaceted Mechanisms of Estradiol and Estrogen
582 Receptor Signaling. *Journal of Biological Chemistry* 276:36869–36872.
- 583 Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Ström A.,
584 Treuter E., Warner M., Gustafsson J-A. 2007. Estrogen receptors: how do they signal and
585 what are their targets. *Physiological reviews* 87:905–31.
- 586 Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. 2007. qBase relative
587 quantification framework and software for management and automated analysis of real-time
588 quantitative PCR data. *Genome biology* 8:R19.
- 589 Hillegass JM., Villano CM., Cooper KR., White LA. 2007a. Matrix metalloproteinase-13 is
590 required for zebra fish (*Danio rerio*) development and is a target for glucocorticoids.
591 *Toxicological sciences : an official journal of the Society of Toxicology* 100:168–79.
- 592 Hillegass JM., Villano CM., Cooper KR., White LA. 2007b. Glucocorticoids Alter Craniofacial
593 Development and Increase Expression and Activity of Matrix Metalloproteinases in
594 Developing Zebrafish (*Danio rerio*). *Toxicological Sciences* 102:413–424.
- 595 Hu Y., Albertson RC. 2014. Hedgehog signaling mediates adaptive variation in a dynamic
596 functional system in the cichlid feeding apparatus. *Proceedings of the National Academy of*
597 *Sciences of the United States of America* 111:8530–4.
- 598 Hu D., Colnot C., Marcucio RS. 2008. Effect of bone morphogenetic protein signaling on
599 development of the jaw skeleton. *Developmental Dynamics* 237:3727–3737.
- 600 Hu D., Helms J. 1999. The role of sonic hedgehog in normal and abnormal craniofacial
601 morphogenesis. *Development* 126:4873–4884.

- 602 Jenei-Lanzl Z., Straub RH., Dienstknecht T., Huber M., Hager M., Grässel S., Kujat R., Angele
603 MK., Nerlich M., Angele P. 2010. Estradiol inhibits chondrogenic differentiation of
604 mesenchymal stem cells via nonclassic signaling. *Arthritis and rheumatism* 62:1088–96.
- 605 Jia M., Dahlman-Wright K., Gustafsson J-Å. 2015. Estrogen receptor alpha and beta in health
606 and disease. *Best Practice & Research Clinical Endocrinology & Metabolism* 29:557–568.
- 607 Joshi PA., Chang H., Hamel PA. 2006. Loss of Alx4, a stromally-restricted homeodomain
608 protein, impairs mammary epithelial morphogenesis. *Developmental biology* 297:284–94.
- 609 Kubista M., Andrade JM., Bengtsson M., Forootan A., Jonák J., Lind K., Sindelka R., Sjöback
610 R., Sjögreen B., Strömbom L., Ståhlberg A., Zoric N. 2006. The real-time polymerase chain
611 reaction. *Molecular aspects of medicine* 27:95–125.
- 612 Kuratani S., Matsuo I., Aizawa S. 1997. Developmental patterning and evolution of the
613 mammalian viscerocranium: genetic insights into comparative morphology. *Developmental
614 dynamics : an official publication of the American Association of Anatomists* 209:139–55.
- 615 Lam K-K., Cheng P-Y., Hsiao G., Chen S-Y., Shen H-H., Yen M-H., Lee Y-M. 2009. Estrogen
616 deficiency-induced alterations of vascular MMP-2, MT1-MMP, and TIMP-2 in
617 ovariectomized rats. *American journal of hypertension* 22:27–34.
- 618 Lassiter CS., Linney E. 2007. Embryonic expression and steroid regulation of brain aromatase
619 cyp19a1b in zebrafish (*Danio rerio*). *Zebrafish* 4:49–57.
- 620 Lee Y-H., Saint-Jeannet J-P. 2011. Sox9 function in craniofacial development and disease.
621 *Genesis (New York, N.Y. : 2000)* 49:200–8.
- 622 Lehane DB., McKie N., Russell RG., Henderson IW. 1999. Cloning of a fragment of the
623 osteonectin gene from goldfish, *Carassius auratus*: its expression and potential regulation by
624 estrogen. *General and comparative endocrinology* 114:80–7.
- 625 Letra A., Silva RM., Motta LG., Blanton SH., Hecht JT., Granjeirol JM., Vieira AR. 2012.
626 Association of MMP3 and TIMP2 promoter polymorphisms with nonsyndromic oral clefts.
627 *Birth defects research. Part A, Clinical and molecular teratology* 94:540–8.
- 628 Lézot F., Chesneau J., Navet B., Gobin B., Amiaud J., Choi Y., Yagita H., Castaneda B., Berdal
629 A., Mueller CG., Rédini F., Heymann D. 2015. Skeletal consequences of RANKL-blocking
630 antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect
631 with zoledronic acid. *Bone* 73:51–9.
- 632 Lin C., Spikings E., Zhang T., Rawson D. 2009. Housekeeping genes for cryopreservation
633 studies on zebrafish embryos and blastomeres. *Theriogenology* 71:1147–55.
- 634 Linville A., Radtke K., Waxman JS., Yelon D., Schilling TF. 2009. Combinatorial roles for
635 zebrafish retinoic acid receptors in the hindbrain, limbs and pharyngeal arches.

- 636 *Developmental biology* 325:60–70.
- 637 Liu C., Xin N., Zhai Y., Jiang L., Zhai J., Zhang Q., Qi J. 2014. Reference gene selection for
638 quantitative real-time RT-PCR normalization in the half-smooth tongue sole (*Cynoglossus*
639 *semilaevis*) at different developmental stages, in various tissue types and on exposure to
640 chemicals. *PloS one* 9:e91715.
- 641 Lohnes D., Mark M., Mendelsohn C., Dolle P., Dierich A., Gorry P., Gansmuller A., Chambon
642 P. 1994. Function of the retinoic acid receptors (RARs) during development (I).
643 Craniofacial and skeletal abnormalities in RAR double mutants. *Development* 120:2723–
644 2748.
- 645 Loth SR., Henneberg M. 2001. Sexually dimorphic mandibular morphology in the first few years
646 of life. *American journal of physical anthropology* 115:179–86.
- 647 Lours-Calet C., Alvares LE., El-Hanfy AS., Gandesha S., Walters EH., Sobreira DR., Wotton
648 KR., Jorge EC., Lawson JA., Kelsey Lewis A., Tada M., Sharpe C., Kardon G., Dietrich S.
649 2014. Evolutionarily conserved morphogenetic movements at the vertebrate head-trunk
650 interface coordinate the transport and assembly of hypopharyngeal structures.
651 *Developmental biology* 390:231–46.
- 652 Lu T., Achari Y., Sciore P., Hart DA. 2006. Estrogen receptor alpha regulates matrix
653 metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional
654 regulatory site. *Biochimica et biophysica acta* 1762:719–31.
- 655 Maddox BK., Garofalo S., Horton WA., Richardson MD., Trune DR. Craniofacial and otic
656 capsule abnormalities in a transgenic mouse strain with a *Col2a1* mutation. *Journal of*
657 *craniofacial genetics and developmental biology* 18:195–201.
- 658 Magnani L., Ballantyne EB., Zhang X., Lupien M. 2011. PBX1 genomic pioneer function drives
659 ER α signaling underlying progression in breast cancer. *PLoS genetics* 7:e1002368.
- 660 Maneix L., Servent A., Porée B., Ollitrault D., Branly T., Bigot N., Boujrad N., Flouriot G.,
661 Demoor M., Boumediene K., Moslemi S., Galéra P. 2014. Up-regulation of type II collagen
662 gene by 17 β -estradiol in articular chondrocytes involves Sp1/3, Sox-9, and estrogen
663 receptor α . *Journal of molecular medicine (Berlin, Germany)*.
- 664 Marazita ML. 2012. The evolution of human genetic studies of cleft lip and cleft palate. *Annual*
665 *review of genomics and human genetics* 13:263–83.
- 666 Marin-Castaño ME., Elliot SJ., Potier M., Karl M., Striker LJ., Striker GE., Csaky KG., Cousins
667 SW. 2003. Regulation of estrogen receptors and MMP-2 expression by estrogens in human
668 retinal pigment epithelium. *Investigative ophthalmology & visual science* 44:50–9.
- 669 Marquez Hernandez RA., Ohtani J., Fujita T., Sunagawa H., Kawata T., Kaku M., Motokawa

- 670 M., Tanne K. 2011. Sex hormones receptors play a crucial role in the control of femoral and
671 mandibular growth in newborn mice. *The European Journal of Orthodontics* 33:564–569.
- 672 McCarthy TL., Chang W-Z., Liu Y., Centrella M. 2003. Runx2 integrates estrogen activity in
673 osteoblasts. *The Journal of biological chemistry* 278:43121–9.
- 674 McCurley AT., Callard G V. 2008. Characterization of housekeeping genes in zebrafish: male-
675 female differences and effects of tissue type, developmental stage and chemical treatment.
676 *BMC molecular biology* 9:102.
- 677 Mosig RA., Dowling O., DiFeo A., Ramirez MCM., Parker IC., Abe E., Diouri J., Aqeel A Al.,
678 Wylie JD., Oblander SA., Madri J., Bianco P., Apte SS., Zaidi M., Doty SB., Majeska RJ.,
679 Schaffler MB., Martignetti JA. 2007. Loss of MMP-2 disrupts skeletal and craniofacial
680 development and results in decreased bone mineralization, joint erosion and defects in
681 osteoblast and osteoclast growth. *Human molecular genetics* 16:1113–23.
- 682 Ng KP., Datuin JP., Bern HA. 2001. Effects of estrogens in vitro and in vivo on cartilage growth
683 in the tilapia (*Oreochromis mossambicus*). *General and comparative endocrinology*
684 121:295–304.
- 685 Nie X., Luukko K., Kettunen P. 2006. BMP signalling in craniofacial development. *The*
686 *International journal of developmental biology* 50:511–21.
- 687 Nilsson UW., Garvin S., Dabrosin C. 2007. MMP-2 and MMP-9 activity is regulated by estradiol
688 and tamoxifen in cultured human breast cancer cells. *Breast cancer research and treatment*
689 102:253–61.
- 690 O’Lone R., Frith MC., Karlsson EK., Hansen U. 2004. Genomic targets of nuclear estrogen
691 receptors. *Molecular endocrinology (Baltimore, Md.)* 18:1859–75.
- 692 Obayashi T., Kinoshita K. 2011. COXPRESdb: a database to compare gene coexpression in
693 seven model animals. *Nucleic acids research* 39:D1016–22.
- 694 Oginni FO., Adenekan AT. 2012. Prevention of oro-facial clefts in developing world. *Annals of*
695 *maxillofacial surgery* 2:163–9.
- 696 Page-McCaw A., Ewald AJ., Werb Z. 2007. Matrix metalloproteinases and the regulation of
697 tissue remodelling. *Nature reviews. Molecular cell biology* 8:221–33.
- 698 Pelayo S., Oliveira E., Thienpont B., Babin PJ., Raldúa D., André M., Piña B. 2012.
699 Triiodothyronine-induced changes in the zebrafish transcriptome during the
700 eleutheroembryonic stage: implications for bisphenol A developmental toxicity. *Aquatic*
701 *toxicology (Amsterdam, Netherlands)* 110-111:114–22.
- 702 Petrey AC., Flanagan-Steet H., Johnson S., Fan X., De la Rosa M., Haskins ME., Nairn A V.,
703 Moremen KW., Steet R. 2012. Excessive activity of cathepsin K is associated with cartilage

- 704 defects in a zebrafish model of mucopolidosis II. *Disease models & mechanisms* 5:177–90.
- 705 Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR.
706 *Nucleic acids research* 29:e45.
- 707 Pfaffl MW., Tichopad A., Prgomet C., Neuvians TP. 2004. Determination of stable
708 housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper-
709 -Excel-based tool using pair-wise correlations. *Biotechnology letters* 26:509–15.
- 710 Powder KE., Milch K., Asselin G., Albertson RC. 2015. Constraint and diversification of
711 developmental trajectories in cichlid facial morphologies. *EvoDevo* 6:25.
- 712 Qu S., Tucker SC., Zhao Q., deCrombrughe B., Wisdom R. 1999. Physical and genetic
713 interactions between Alx4 and Cart1. *Development (Cambridge, England)* 126:359–69.
- 714 Ramakers C., Ruijter JM., Deprez RHL., Moorman AFM. 2003. Assumption-free analysis of
715 quantitative real-time polymerase chain reaction (PCR) data. *Neuroscience letters* 339:62–
716 6.
- 717 Renn J., Schaedel M., Volff J-N., Goerlich R., Schartl M., Winkler C. 2006. Dynamic expression
718 of sparc precedes formation of skeletal elements in the Medaka (*Oryzias latipes*). *Gene*
719 372:208–18.
- 720 Roberts RB., Hu Y., Albertson RC., Kocher TD. 2011. Craniofacial divergence and ongoing
721 adaptation via the hedgehog pathway. *Proceedings of the National Academy of Sciences of*
722 *the United States of America* 108:13194–9.
- 723 Rotllant J., Liu D., Yan Y-L., Postlethwait JH., Westerfield M., Du S-J. 2008. Sparc
724 (Osteonectin) functions in morphogenesis of the pharyngeal skeleton and inner ear. *Matrix*
725 *biology : journal of the International Society for Matrix Biology* 27:561–72.
- 726 Sanger TJ., Seav SM., Tokita M., Langerhans RB., Ross LM., Losos JB., Abzhanov A. 2014.
727 The oestrogen pathway underlies the evolution of exaggerated male cranial shapes in Anolis
728 lizards. *Proceedings. Biological sciences / The Royal Society* 281:20140329.
- 729 Satoh W., Gotoh T., Tsunematsu Y., Aizawa S., Shimono A. 2006. Sfrp1 and Sfrp2 regulate
730 anteroposterior axis elongation and somite segmentation during mouse embryogenesis.
731 *Development (Cambridge, England)* 133:989–99.
- 732 Schiller V., Wichmann A., Kriehuber R., Schäfers C., Fischer R., Fenske M. 2013.
733 Transcriptome alterations in zebrafish embryos after exposure to environmental estrogens
734 and anti-androgens can reveal endocrine disruption. *Reproductive toxicology (Elmsford,*
735 *N.Y.)* 42:210–23.
- 736 Sears KE., Goswami A., Flynn JJ., Niswander LA. The correlated evolution of Runx2 tandem
737 repeats, transcriptional activity, and facial length in carnivora. *Evolution & development*

- 738 9:555–65.
- 739 Selleri L., Depew MJ., Jacobs Y., Chanda SK., Tsang KY., Cheah KS., Rubenstein JL.,
740 O’Gorman S., Cleary ML. 2001. Requirement for Pbx1 in skeletal patterning and
741 programming chondrocyte proliferation and differentiation. *Development (Cambridge,
742 England)* 128:3543–57.
- 743 Sgouras DN., Athanasiou MA., Beal GJ., Fisher RJ., Blair DG., Mavrothalassitis GJ. 1995. ERF:
744 an ETS domain protein with strong transcriptional repressor activity, can suppress ets-
745 associated tumorigenesis and is regulated by phosphorylation during cell cycle and
746 mitogenic stimulation. *The EMBO journal* 14:4781–93.
- 747 Shi Y., Liu X., Zhu P., Li J., Sham K W Y., Cheng SH., Li S., Zhang Y., Cheng CHK., Lin H.
748 2013. G-protein-coupled estrogen receptor 1 is involved in brain development during
749 zebrafish (*Danio rerio*) embryogenesis. *Biochemical and biophysical research
750 communications* 435:21–7.
- 751 Stender JD., Kim K., Charn TH., Komm B., Chang KCN., Kraus WL., Benner C., Glass CK.,
752 Katzenellenbogen BS. 2010. Genome-wide analysis of estrogen receptor alpha DNA
753 binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-
754 mediated transcriptional activation. *Molecular and cellular biology* 30:3943–55.
- 755 Sumarsono SH., Wilson TJ., Tymms MJ., Venter DJ., Corrick CM., Kola R., Lahoud MH.,
756 Papas TS., Seth A., Kola I. 1996. Down’s syndrome-like skeletal abnormalities in Ets2
757 transgenic mice. *Nature* 379:534–7.
- 758 Swartz ME., Nguyen V., McCarthy NQ., Eberhart JK. 2012. Hh signaling regulates patterning
759 and morphogenesis of the pharyngeal arch-derived skeleton. *Developmental biology*
760 369:65–75.
- 761 Syed FA., Mödder U IL., Fraser DG., Spelsberg TC., Rosen CJ., Krust A., Chambon P., Jameson
762 JL., Khosla S. 2005. Skeletal Effects of Estrogen Are Mediated by Opposing Actions of
763 Classical and Nonclassical Estrogen Receptor Pathways. *Journal of Bone and Mineral
764 Research* 20:1992–2001.
- 765 Szabo-Rogers HL., Smithers LE., Yakob W., Liu KJ. 2010. New directions in craniofacial
766 morphogenesis. *Developmental biology* 341:84–94.
- 767 Tang R., Dodd A., Lai D., McNabb WC., Love DR. 2007. Validation of zebrafish (*Danio rerio*)
768 reference genes for quantitative real-time RT-PCR normalization. *Acta biochimica et
769 biophysica Sinica* 39:384–90.
- 770 Tankó LB., Søndergaard B-C., Oestergaard S., Karsdal MA., Christiansen C. 2008. An update
771 review of cellular mechanisms conferring the indirect and direct effects of estrogen on
772 articular cartilage. *Climacteric : the journal of the International Menopause Society* 11:4–

- 773 16.
- 774 Thisse B., Pflumio S., Fürthauer M., Loppin B., Heyer V., Degrave A., Woehl R., Lux A.,
775 Steffan T., Charbonnier XQ., And., Thisse C. 2001. Expression of the zebrafish genome
776 during embryogenesis (NIH R01 RR15402). *ZFIN Direct Data Submission* (<http://zfin.org>).
- 777 Thisse B., Heyer V., Lux A., Alunni V., Degrave A., Seiliez I., Kirchner J., Parkhill J-P., Thisse
778 C. 2004. Spatial and temporal expression of the zebrafish genome by large-scale in situ
779 hybridization screening. *Methods in cell biology* 77:505–19.
- 780 Thisse, C., and Thisse B. 2005. High Throughput Expression Analysis of ZF-Models Consortium
781 Clones. *ZFIN Direct Data Submission* (<http://zfin.org>).
- 782 Trainor PA., Melton KR., Manzanares M. 2003. Origins and plasticity of neural crest cells and
783 their roles in jaw and craniofacial evolution. *The International journal of developmental*
784 *biology* 47:541–53.
- 785 Trevant B., Gaur T., Hussain S., Symons J., Komm BS., Bodine PVN., Stein GS., Lian JB. 2008.
786 Expression of secreted frizzled related protein 1, a Wnt antagonist, in brain, kidney, and
787 skeleton is dispensable for normal embryonic development. *Journal of cellular physiology*
788 217:113–26.
- 789 Troen BR. 2006. The regulation of cathepsin K gene expression. *Annals of the New York*
790 *Academy of Sciences* 1068:165–72.
- 791 Tüshaus L., Hopert A-C., Strunck E., Schubert C., Wünsche W., Vollmer G. 2003. Estrogenic
792 and antiestrogenic regulation of MMP-2 and MMP-13 mRNA in RUCA-I endometrial
793 tumor cells in vitro and in vivo. *Cancer Letters* 198:99–106.
- 794 Twigg SRF., Vorgia E., McGowan SJ., Peraki I., Fenwick AL., Sharma VP., Allegra M.,
795 Zaragkoulias A., Sadighi Akha E., Knight SJL., Lord H., Lester T., Izatt L., Lampe AK.,
796 Mohammed SN., Stewart FJ., Verloes A., Wilson LC., Healy C., Sharpe PT., Hammond P.,
797 Hughes J., Taylor S., Johnson D., Wall SA., Mavrothalassitis G., Wilkie AOM. 2013.
798 Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links
799 ERK1/2 signaling to regulation of osteogenesis. *Nature genetics* 45:308–13.
- 800 Vanacker JM., Delmarre C., Guo X., Laudet V. 1998. Activation of the osteopontin promoter by
801 the orphan nuclear receptor estrogen receptor related alpha. *Cell growth & differentiation :*
802 *the molecular biology journal of the American Association for Cancer Research* 9:1007–14.
- 803 Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F.
804 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric
805 averaging of multiple internal control genes. *Genome biology* 3:RESEARCH0034.
- 806 Venkatesh B., Lee AP., Ravi V., Maurya AK., Lian MM., Swann JB., Ohta Y., Flajnik MF.,


- 807 Sutoh Y., Kasahara M., Hoon S., Gangu V., Roy SW., Irimia M., Korzh V., Kondrychyn I.,
808 Lim ZW., Tay B-H., Tohari S., Kong KW., Ho S., Lorente-Galdos B., Quilez J., Marques-
809 Bonet T., Raney BJ., Ingham PW., Tay A., Hillier LW., Minx P., Boehm T., Wilson RK.,
810 Brenner S., Warren WC. 2014. Elephant shark genome provides unique insights into
811 gnathostome evolution. *Nature* 505:174–9.
- 812 Wang E., Wang K., Chen D., Wang J., He Y., Long B., Yang L., Yang Q., Geng Y., Huang X.,
813 Ouyang P., Lai W. 2015. Evaluation and Selection of Appropriate Reference Genes for
814 Real-Time Quantitative PCR Analysis of Gene Expression in Nile Tilapia (*Oreochromis*
815 *niloticus*) during Vaccination and Infection. *International journal of molecular sciences*
816 16:9998–10015.
- 817 Wang J., Ma X. 2012. Effects of estrogen and progestin on expression of MMP-2 and TIMP-2 in
818 a nude mouse model of endometriosis. *Clinical and experimental obstetrics & gynecology*
819 39:229–33.
- 820 Warner KE., Jenkins JJ. 2007. Effects of 17alpha-ethinylestradiol and bisphenol A on vertebral
821 development in the fathead minnow (*Pimephales promelas*). *Environmental toxicology and*
822 *chemistry / SETAC* 26:732–7.
- 823 Werb Z., Chin JR. 1998. Extracellular matrix remodeling during morphogenesis. *Annals of the*
824 *New York Academy of Sciences* 857:110–8.
- 825 Whyte MP., Obrecht SE., Finnegan PM., Jones JL., Podgornik MN., McAlister WH., Mumm S.
826 2002. Osteoprotegerin deficiency and juvenile Paget’s disease. *The New England journal of*
827 *medicine* 347:175–84.
- 828 Yamamoto T., Saatcioglu F., Matsuda T. 2013. Cross-Talk between Bone Morphogenic Proteins
829 and Estrogen Receptor Signaling. *Endocrinology*.
- 830 Yan Y-L., Willoughby J., Liu D., Crump JG., Wilson C., Miller CT., Singer A., Kimmel C.,
831 Westerfield M., Postlethwait JH. 2005. A pair of Sox: distinct and overlapping functions of
832 zebrafish *sox9* co-orthologs in craniofacial and pectoral fin development. *Development*
833 (*Cambridge, England*) 132:1069–83.
- 834 Yokota T., Oritani K., Garrett KP., Kouro T., Nishida M., Takahashi I., Ichii M., Satoh Y.,
835 Kincade PW., Kanakura Y. 2008. Soluble Frizzled-Related Protein 1 Is Estrogen Inducible
836 in Bone Marrow Stromal Cells and Suppresses the Earliest Events in Lymphopoiesis. *The*
837 *Journal of Immunology* 181:6061–6072.
- 838 Zhou S., Turgeman G., Harris SE., Leitman DC., Komm BS., Bodine PVN., Gazit D. 2003.
839 Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal
840 stem cells. *Molecular endocrinology (Baltimore, Md.)* 17:56–66.

841

1

Expression analysis of candidate reference genes in developing heads of zebrafish larvae across control and E₂ treated groups.

(A) Expression profiles of candidate reference genes in raw Cq values for all samples (3 treatments for each of 5 larval stages and with 3 biological replicates). The middle line denotes the median and boxes indicate the 25/75 percentiles. **(B)** Expression differences of candidate reference genes in the head of zebrafish during the larval development and three E₂ treatment groups. Fold changes in expression calculated from the qPCR data, were subjected to ANOVA and Tukey's HSD analysis to test the expression differences amongst three treatment groups (control, 2μM and 5μM) and across five larval stages (3 to 7dpf). White boxes represent low expression, while black boxes represent high expression. Two or more steps of shade differences in the boxes represent significantly different expression between the samples (alpha = 0.05). NS = not significant.


A**B**

Gene	ANOVA treatments	HSD treatments			ANOVA larval stage	HSD larval stage				
		Ctl	2 μ M	5 μ M		3dpf	4dpf	5dpf	6dpf	7dpf
<i>actb1</i>	$P = 0.039$	Ctl	2 μ M	5 μ M	$P = 9.77e-08$	3dpf	4dpf	5dpf	6dpf	7dpf
<i>elfa</i>	$P = 0.758$	NS			$P = 3.44e-06$	3dpf	4dpf	5dpf	6dpf	7dpf
<i>gapdh</i>	$P = 0.437$	NS			$P = 0.002$	3dpf	4dpf	5dpf	6dpf	7dpf
<i>ppia2</i>	$P = 0.64$	NS			$P = 0.001$	3dpf	4dpf	5dpf	6dpf	7dpf
<i>rpl8</i>	$P = 0.084$	NS			$P = 2.04e-05$	3dpf	4dpf	5dpf	6dpf	7dpf
<i>tbp</i>	$P = 0.532$	NS			$P = 0.752$	NS				
<i>tuba1</i>	$P = 0.502$	NS			$P = 1.4e-13$	3dpf	4dpf	5dpf	6dpf	7dpf

2

Expression differences of two estrogen receptors and components of hedgehog signaling pathway in developing heads of zebrafish larvae across control and E₂ treated groups.


Expression of *esrra*, *esr1*, *ptch1*, *ptch2*, *shha* and *shhb* was examined with qPCR and normalised using three highest ranked reference genes (*ppia2*, *rpl8* and *tbp*). For analysis of relative expression levels for each target gene a replicate of the control group at 3dpf was set to one. The white, grey, and black bars in each graph represent expression levels for control, 2µM E₂ treated and 5µM E₂ treated groups respectively. Statistical differences of each treatment group versus the others are shown in white, grey, and black circles representing higher expressed than control, 2µM E₂ treated and 5µM E₂ treated groups respectively (P < 0.05). Error bars represent standard deviation calculated from three biological replicates. Each biological replicate is from a homogenate of 30 heads.



3

Expression differences of six potential skeletogenic targets of estrogen pathway in developing heads of zebrafish larvae across control and E₂ treated groups.


Expression of *bmp2a*, *bmp2b*, *opg*, *rankl*, *runx2b* and *sox9b* was examined with qPCR and normalised using three highest ranked reference genes (*ppia2*, *rpl8* and *tbp*). For analysis of relative expression levels for each target gene a replicate of the control group at 3dpf was set to one. The white, grey, and black bars in each graph represent expression levels for control, 2 μ M E₂ treated and 5 μ M E₂ treated groups respectively. Statistical differences of each treatment group versus the others are shown in white, grey, and black circles representing higher expressed than control, 2 μ M E₂ treated and 5 μ M E₂ treated groups respectively (P < 0.05). Error bars represent standard deviation calculated from three biological replicates. Each biological replicate was made from a homogenate of 30 heads.



4

Expression differences of eight potential targets of estrogen pathway involved in skeletal ECM formation examined during zebrafish larval head development across control and E₂ treated groups.


Expression of *col2a1a*, *ctsk*, *mmp2*, *mmp9*, *mmp13*, *sparc*, *spp1* and *timp2* was examined with qPCR and normalised using three highest ranked reference genes (*ppia2*, *rpl8* and *tbp*). For analysis of relative expression levels for each target gene a replicate of the control group at 3dpf was set to one. The white, grey, and black bars in each graph represent expression levels for control, 2µM E₂ treated and 5µM E₂ treated groups respectively. Statistical differences of each treatment group versus the others are shown in white, grey, and black circles representing higher expressed than control, 2µM E₂ treated and 5µM E₂ treated groups respectively (P < 0.05). Error bars represent standard deviation calculated from three biological replicates. Each biological replicate was made from a homogenate of 30 heads.



5

Expression differences of eight other potential targets of estrogen pathway involved in jaw skeletal elongation examined during zebrafish larval head development across control and E₂ treated groups.

Expression of *alx4*, *dlx1*, *erf*, *ets2*, *pbx1a*, *pbx1b*, *rarab* and *sfrp1a* was examined with qPCR and normalised using three best ranked reference genes (*ppia2*, *rpl8* and *tbp*). For analysis of relative expression levels for each target gene a replicate of the control group at 3dpf was set to one. The white, grey, and black bars in each graph represent expression levels for control, 2µM E₂ treated and 5µM E₂ treated groups respectively. Statistical differences of each treatment group versus the others are shown in white, grey, and black circles representing higher expressed than control, 2µM E₂ treated and 5µM E₂ treated groups respectively (P < 0.05). Error bars represent standard deviation calculated from three biological replicates. Each biological replicate was made from a homogenate of 30 heads.



6

Expression differences of *esr1* coexpressed genes in developing heads of zebrafish larvae across control and E₂ treated groups.

Expression levels of eleven candidate genes coexpressed with *esr1*, based on data from COXPRESdb in zebrafish, were examined with qPCR and normalised using three best ranked reference genes (*ppia2*, *rpl8* and *tbp*). For analysis of relative expression levels for each target gene a replicate of the control group at 3dpf was set to one. The white, grey, and black bars in each graph represent expression levels for control, 2µM E₂ treated and 5µM E₂ treated groups respectively. Statistical differences of each treatment group versus the others are shown in white, grey, and black circles representing higher expressed than in control, 2µM E₂ treated and 5µM E₂ treated groups respectively (P < 0.05). Error bars represent standard deviation calculated from three biological replicates. Each biological replicate is based on a homogenate of 30 heads.




Table 1 (on next page)

Selected putative estrogen-regulated candidate genes, and available literature indicating their role in craniofacial development/skeletal formation in zebrafish or other vertebrates.

Gene Symbol	Related Function	Viscerocranial expression during zebrafish development	Potential Estrogen Responsive *	Craniofacial skeletogenesis		References
				Shortened snout **	Other effects	
<i>alx4</i>	Patterning and development of craniofacial skeleton	+	+	+	+	(Qu et al., 1999; Joshi, Chang & Hamel, 2006; Lours-Calet et al., 2014)
<i>bmp2</i> (a/b)	Induction of bone and cartilage formation	+	+	?	+	(Thisse et al., 2001, 2004; Zhou et al., 2003; Nie, Luukko & Kettunen, 2006; Hu, Colnot & Marcucio, 2008; Yamamoto, Saatcioglu & Matsuda, 2013)
<i>col2a1a</i>	Extracellular matrix formation in cartilaginous tissues	+	+	+	+	(Maddox et al.; Eames et al., 2010; Maneix et al., 2014)
<i>ctsk</i>	Bone remodelling and resorption	+	+	+	+	(Thisse et al., 2004; Troen, 2006; Petrey et al., 2012; Ahi et al., 2014)
<i>dlk1</i>	Differentiation of skeletal cells	?	+	+	+	(Abdallah et al., 2011)
<i>erf</i>	Regulation of cellular senescence	?	+	+	+	(Frasor et al., 2003; Twigg et al., 2013)
<i>esrra</i>	Regulation of estrogen mediated pathway	+	+	?	+	(Bonnelye & Aubin, 2005; Bonnelye et al., 2007; Auld et al., 2012)
<i>esr1</i>	A ligand-activated receptor for estrogen	?	+	?	+	(O'Lone et al., 2004; Syed et al., 2005)
<i>ets2</i>	Regulation of developmental genes and apoptosis	?	+	+	+	(Sumarsono et al., 1996; Deblois et al., 2009; Ahi et al., 2014)
<i>mmp</i> (2/9/13)	Extracellular matrix formation and signal transduction	+	+	+	+	(Breckon et al., 1999; Tüshaus et al., 2003; Marin-Castaño et al., 2003; Lu et al., 2006; Hillegass et al., 2007a,b; Mosig et al., 2007; Nilsson, Garvin & Dabrosin, 2007)
<i>opg</i>	Negative regulation of bone resorption	?	+	?	+	(Bord et al., 2003)(Whyte et al., 2002)
<i>pbx1</i> (a/b)	co-ordination of chondrocyte proliferation and differentiation	+	+	+	+	(Selleri et al., 2001; Thisse, C., and Thisse, 2005; Magnani et al., 2011)
<i>ptch</i> (1/2)	Receptors for hedgehog signalling pathway	+	+	+	+	(Fushimi et al., 2009; Roberts et al., 2011)
<i>rankl</i>	Osteoclast differentiation and activation	?	+	?	+	(Bord et al., 2003; Lézot et al., 2015)
<i>rarb</i>	A receptor for retinoic acid signalling pathway	+	+	+	+	(Lohnes et al., 1994; O'Lone et al., 2004; Linville et al., 2009)
<i>runx2b</i>	Osteoblast differentiation and skeletal morphogenesis	+	+	+	+	(Sears et al.; McCarthy et al., 2003; Flores et al., 2006)
<i>sfrp1a</i>	A soluble modulator of Wnt signalling pathway	?	+	+	+	(Sato et al., 2006; Trevant et al., 2008; Yokota et al., 2008; Fukuhara et al., 2013; Ahi et al., 2014)

<i>Shh</i> (a/b)	Activators of hedgehog signalling pathway	+	?	?	+	(Hu & Helms, 1999; Swartz et al., 2012)
<i>sox9b</i>	Chondrocyte differentiation	+	+	?	+	(Yan et al., 2005; Bonnelye et al., 2007; Lee & Saint-Jeannet, 2011)
<i>sparc</i>	Extracellular matrix synthesis and regulation of cell growth	+	+	+	+	(Lehane et al., 1999; Renn et al., 2006; Rotllant et al., 2008)
<i>spp1</i>	Attachment of osteoclasts to ECM in bone	+	+	+	+	(Craig & Denhardt, 1991; Vanacker et al., 1998; Venkatesh et al., 2014)
<i>timp2a</i>	Inhibition of mmmps and regulation of tissue homeostasis	?	+	+	?	(Dew et al., 2000; Lam et al., 2009; Letra et al., 2012; Wang & Ma, 2012; Ahi et al., 2014)

* The estrogen responsiveness indicates either transcriptional regulation or transactivation and the related information are mainly obtained from different model vertebrates, such as human and mouse, than teleost fishes.

** The shortened snout indicates the skeletal effects resulted from decrease in the length or changes in morphology of viscerocranial skeletal elements in different vertebrate species. This could bear a resemblance to estrogen mediated shorter snout and flatter face phenotype in zebrafish.

1

2

Table 2 (on next page)

Ranking and statistical analyses of candidate reference genes using BestKeeper, geNorm and NormFinder.

1

BestKeeper				geNorm		NormFinder	
Ranking	r	Ranking	SD	Ranking	M	Ranking	SV
<i>rpl8</i>	0.908	<i>tbp</i>	0.294	<i>ppia2</i>	0.111	<i>rpl8</i>	0.137
<i>tbp</i>	0.863	<i>rpl8</i>	0.343	<i>rpl8</i>	0.125	<i>ppia2</i>	0.154
<i>ppia2</i>	0.862	<i>ppia2</i>	0.350	<i>tbp</i>	0.133	<i>tbp</i>	0.157
<i>actb1</i>	0.687	<i>actb1</i>	0.396	<i>actb1</i>	0.26	<i>actb1</i>	0.287
<i>efl1a</i>	0.331	<i>efl1a</i>	1.358	<i>efl1a</i>	0.739	<i>efl1a</i>	1.128
<i>tubal</i>	0.201	<i>gapdh</i>	1.690	<i>gapdh</i>	1.084	<i>gapdh</i>	1.382
<i>gapdh</i>	0.148	<i>tubal</i>	2.773	<i>tubal</i>	1.482	<i>tubal</i>	2.088

2

3 Abbreviations: SD = Standard deviation, r = Pearson product-moment correlation coefficient, SV
 4 = stability value, M = M value of stability.